Generic Phexxi Availability
Last updated on Apr 10, 2025.
Phexxi is a brand name of citric acid/lactic acid/potassium bitartrate topical, approved by the FDA in the following formulation(s):
PHEXXI (citric acid; lactic acid; potassium bitartrate - gel;vaginal)
-
Manufacturer: EVOFEM INC
Approval date: May 22, 2020
Strength(s): 1%;1.8%;0.4% [RLD]
Is there a generic version of Phexxi available?
No. There is currently no therapeutically equivalent version of Phexxi available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Phexxi. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Compositions and methods for enhancing the efficacy of contraceptive microbicides
Patent 10,568,855
Issued: February 25, 2020
Inventor(s): Guthrie Wendell
Assignee(s): Evofem, Inc.The present disclosure relates to compositions and methods for contraception that also enhance the efficacy of microbicides. Such compositions serve the dual purpose of preventing pregnancy and lessening the risk of spreading sexually transmitted diseases. More specifically, the compositions and methods relate to syngergistic contraceptive microbicide and antiviral compositions comprising a combination of a contraceptive microbicide and an antiviral agent in an acidic carrier that enhances the efficacy of both the contraceptive microbicide and antiviral agent.
Patent expiration dates:
- March 15, 2033✓
- March 15, 2033
-
Compositions and methods for inhibiting inflammation and diseases using an alginic acid-based antimicrobial compound
Patent 11,337,989
Issued: May 24, 2022
Inventor(s): Guthrie; Wendell et al.
Assignee(s): Evofem, Inc. (San Diego, CA)The present disclosure relates to compositions and methods for inhibiting inflammation and reducing the risk of spreading sexually transmitted diseases using an alginic acid-based antimicrobial compound. Such compositions provide dual protection by (1) attacking and inactivating viruses and other microbes and (2) blocking the host response that viruses trigger to invade host cells. Such compositions can also be part of an acid buffering contraceptive.
Patent expiration dates:
- March 15, 2033✓
- March 15, 2033
-
Compositions and methods for enhancing the efficacy of contraceptive microbicides
Patent 11,439,610
Issued: September 13, 2022
Inventor(s): Guthrie Wendell
Assignee(s): Evofem, Inc.The present disclosure relates to compositions and methods for contraception that also enhance the efficacy of microbicides. Such compositions serve the dual purpose of preventing pregnancy and lessening the risk of spreading sexually transmitted diseases. More specifically, the compositions and methods relate to synergistic contraceptive microbicide and antiviral compositions comprising a combination of a contraceptive microbicide and an antiviral agent in an acidic carrier that enhances the efficacy of both the contraceptive microbicide and antiviral agent.
Patent expiration dates:
- March 15, 2033✓✓
- March 15, 2033
-
Compositions and methods for enhancing the efficacy of contraceptive microbicides
Patent 11,992,472
Issued: May 28, 2024
Inventor(s): Guthrie; Wendell
Assignee(s): Evofem, Inc. (San Diego, CA)The present disclosure relates to compositions and methods for contraception that also enhance the efficacy of microbicides. Such compositions serve the dual purpose of preventing pregnancy and lessening the risk of spreading sexually transmitted diseases. More specifically, the compositions and methods relate to syngergistic contraceptive microbicide and antiviral compositions comprising a combination of a contraceptive microbicide and an antiviral agent in an acidic carrier that enhances the efficacy of both the contraceptive microbicide and antiviral agent.
Patent expiration dates:
- March 15, 2033✓
- March 15, 2033
More about Phexxi (citric acid/lactic acid/potassium bitartrate topical)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (28)
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: miscellaneous vaginal agents
- En español
Patient resources
Related treatment guides
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.